Remi Bader, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Remi Bader, Maintenance, and What Happens If You Stop

Remi Bader's Public Timeline with Ozempic

Remi Bader, a plus-size model and influencer with millions of followers across TikTok and Instagram, has been unusually transparent about her experience with GLP-1 receptor agonist medication. In multiple public interviews and social media posts throughout 2022 and 2023, Bader confirmed she had been prescribed Ozempic (semaglutide 1 mg) and used it for a period before discontinuing.

Bader described her post-discontinuation experience in blunt terms during a September 2022 appearance, stating she gained back more weight than she had originally lost. She discussed the experience on TikTok and in interviews with outlets including People magazine, framing her story as a cautionary example for others considering the medication without a long-term plan.

By 2023, Bader publicly disclosed that she had undergone bariatric surgery. She was clear that this decision came after the GLP-1 experience and represented a different approach to managing her weight long-term.

What makes Bader's account clinically relevant is not celebrity status alone. It is the fact that her described trajectory (initial weight loss, drug cessation, rapid and substantial regain) mirrors a pattern that has now been rigorously documented in randomized controlled trials.

At a glance

  • Confirmed use: Remi Bader publicly confirmed Ozempic (semaglutide) use and subsequent discontinuation
  • Documented outcome: Significant weight regain after stopping, exceeding original lost weight per her public statements
  • Clinical parallel: Her experience aligns with STEP-1 extension data showing ~two-thirds of weight loss reversed within 52 weeks of cessation
  • Subsequent intervention: Bader publicly confirmed bariatric surgery after her GLP-1 experience
  • Key clinical takeaway: GLP-1 receptor agonists treat obesity as a chronic condition; discontinuation without an alternative strategy carries high rebound risk

The Biology of GLP-1 Discontinuation Rebound

To understand what Bader experienced, you need to understand what semaglutide actually does in the body and what happens when that signal disappears.

GLP-1 receptor agonists like semaglutide work through several simultaneous mechanisms. They slow gastric emptying, reduce appetite signaling in the hypothalamus, and improve insulin sensitivity. The net effect is reduced caloric intake and, in many patients, substantial weight loss averaging 15% of body weight at the 68-week mark in the landmark STEP-1 trial.

But these drugs do not reset the body's weight set point. They override it temporarily. The hypothalamic circuits that regulate energy balance treat the drug-suppressed weight as artificially low. When the medication is removed, counter-regulatory hormones (ghrelin rises, leptin falls, peptide YY drops) push appetite and metabolic rate back toward the pre-treatment baseline. This is not a failure of willpower. It is a well-characterized neuroendocrine response that has been documented in obesity research for decades, long before GLP-1 drugs existed.

The speed of regain matters too. Unlike gradual weight fluctuation, post-GLP-1 rebound can be rapid because the appetite suppression lifts quickly once the drug's half-life clears (approximately five weeks for semaglutide). Patients frequently describe a sudden return of food noise, cravings, and hunger intensity that they had not experienced in months.

What the STEP-1 Extension Data Actually Shows

The clearest clinical evidence for what Bader described comes from the STEP-1 trial extension study, published in Diabetes, Obesity and Metabolism in 2022. Researchers followed participants who had lost an average of 17.3% of body weight on semaglutide 2.4 mg (the Wegovy dose, higher than Bader's reported Ozempic 1 mg dose) after they stopped the medication.

The findings were stark. Within one year of discontinuation:

  • Participants regained approximately two-thirds (11.6 percentage points of the 17.3% lost) of the weight they had lost
  • Improvements in waist circumference, blood pressure, and lipid profiles also partially reversed
  • Cardiometabolic benefits that had accumulated during treatment eroded alongside the weight regain

This data reframes the entire conversation. GLP-1 medications, when effective, function more like blood pressure medication or statins than like a course of antibiotics. The condition (obesity, driven by dysregulated appetite signaling) does not resolve when the treatment stops. The STEP-4 trial reinforced this by showing that patients switched from semaglutide to placebo at week 20 regained weight while those who continued lost additional weight through week 68.

The HealthRX Medical Team's perspective: Bader's public account is consistent with what the STEP extension data predicts. A patient who discontinues semaglutide without transitioning to another weight management intervention (whether pharmacological, surgical, or a structured behavioral program) faces a high probability of regain. Her experience is not an outlier. It is the expected clinical outcome based on the current evidence base.

Why Bariatric Surgery After GLP-1 Discontinuation Makes Clinical Sense

Bader's subsequent decision to pursue bariatric surgery is worth examining in clinical context. For patients who have experienced GLP-1 rebound, bariatric surgery represents a mechanistically different intervention. Procedures like sleeve gastrectomy and Roux-en-Y gastric bypass produce durable changes to gut hormone signaling, including sustained elevation of post-prandial GLP-1 levels, reduced ghrelin production from the fundus, and altered bile acid metabolism.

A 2022 meta-analysis in The Lancet confirmed that bariatric surgery produces greater sustained weight loss at five years compared to pharmacotherapy alone, with average maintained loss of 20-30% of body weight depending on procedure type.

This does not mean surgery is universally superior to GLP-1 therapy. The comparison is more nuanced than that. GLP-1 medications are reversible, have a defined side effect profile (primarily gastrointestinal: nausea, vomiting, constipation, and rare but serious risks including pancreatitis and potential thyroid C-cell concerns noted in FDA labeling), and require no operative risk. Surgery carries perioperative risks, is largely irreversible, and requires lifelong nutritional monitoring. But surgery also produces more durable hormonal changes that do not depend on continued pharmaceutical intervention.

For a patient like Bader, who had already demonstrated that GLP-1 monotherapy followed by cessation led to rebound, surgery represented a pivot to a different mechanism of action with stronger long-term durability data.

The Maintenance Question No One Wants to Answer

Bader's story exposes the central tension in the current GLP-1 conversation: these medications work well while patients take them, but the healthcare system, insurance coverage, and public expectation have not fully caught up with the implication that many patients may need them indefinitely.

The American Gastroenterological Association's 2022 clinical practice guideline recommends long-term pharmacotherapy for patients with obesity, explicitly acknowledging that discontinuation leads to weight regain in most cases. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy similarly positions these drugs as chronic treatments, not short courses.

Insurance coverage remains inconsistent. Many plans cover GLP-1 medications for type 2 diabetes but not for obesity alone. Patients who lose coverage, face formulary changes, or cannot sustain out-of-pocket costs (Ozempic and Wegovy can exceed $1,000 per month without insurance) may be forced into exactly the discontinuation scenario Bader experienced. This is not a hypothetical problem. It is a structural one.

The HealthRX Medical Team's perspective: Prescribing a GLP-1 receptor agonist without discussing a discontinuation plan is incomplete care. Every patient starting semaglutide, tirzepatide, or any GLP-1 should have a frank conversation about three scenarios: (1) indefinite continuation, (2) planned transition to a lower-cost or lower-dose maintenance regimen, and (3) what happens if the drug becomes unavailable. Bader's public experience is exactly the kind of real-world outcome that should inform those conversations.

Emerging Strategies for GLP-1 Maintenance and Step-Down

Clinical research is beginning to address the maintenance gap. Several approaches are under investigation or already in clinical use:

Dose reduction rather than full cessation. Some clinicians maintain patients on a lower semaglutide dose (0.25 mg or 0.5 mg weekly) after reaching goal weight, theorizing that partial appetite suppression may prevent full rebound at lower cost and reduced side effect burden. Controlled trial data on this specific strategy remains limited.

Combination with anti-obesity medications. Pairing a reduced GLP-1 dose with oral medications such as phentermine-topiramate or naltrexone-bupropion may sustain some benefit while reducing injectable drug costs.

Transition to tirzepatide or other dual-agonists. Dual GIP/GLP-1 receptor agonists like tirzepatide (Zepbound/Mounjaro) have shown even greater weight loss in head-to-head comparisons, and ongoing studies are evaluating whether their mechanism produces more durable post-cessation effects. The SURMOUNT-4 trial showed that tirzepatide discontinuation also led to regain, though the timeline and magnitude are still being characterized.

Structured behavioral support during and after medication. Pairing pharmacotherapy with cognitive behavioral therapy, structured meal planning, and resistance training may help some patients retain a portion of their weight loss if medication is discontinued, though the data suggests biology will still dominate behavior in most cases.

None of these strategies fully solve the problem. The honest clinical reality is that obesity, like hypertension or type 2 diabetes, tends to require ongoing treatment. The question is which treatment, at what intensity, and for how long.

Frequently asked questions

›
›
›
›
›

References

  • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
  • Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
  • Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/34706171/
  • Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. https://pubmed.ncbi.nlm.nih.gov/27136388/
  • Arterburn DE, et al. Comparative effectiveness of bariatric surgery vs nonsurgical treatment of type 2 diabetes. Lancet. 2022. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01515-6/fulltext
  • FDA. Wegovy (semaglutide) approval for chronic weight management. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
  • Grunvald E, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225. https://pubmed.ncbi.nlm.nih.gov/36356753/
  • Endocrine Society. Pharmacological management of obesity: An Endocrine Society clinical practice guideline. 2024. https://pubmed.ncbi.nlm.nih.gov/38828890/
  • Aronne LJ, et al. Tirzepatide once weekly for the treatment of obesity in people when treatment is withdrawn (SURMOUNT-4). JAMA. 2024. https://pubmed.ncbi.nlm.nih.gov/38376001/